Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).



Short title: Kura KO-TIP 007

Investigated disease: hnscc

Principal Investigator: PD Dr. med. Konrad Klinghammer


Clinic, Institute: Charité Comprehensive Cancer Center

Patient (diseased)
Last change: 05.12.2020

Back to Overview



You are here:

Study Description

Title

Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN).

Short title

Kura KO-TIP 007

EudraCT-No.

2018-001437-40

Scientific Short Description

A Pivotal Study of Tipifarnib in Patients with Recurrent or Metastatic Head and Neck Squamous Cell
Carcinoma (HNSCC) with HRAS mutations who have Failed At least One Prior Line of Therapy

Investigated Disease, Health Issue

ICD-Code
  • C10.0 - Vallecula epiglottica

Characteristics

Studytype

Interventional

Studyphase

2

Back to Overview